Conversion of particulate tyrosinase to soluble form and to desialylated tyrosinase in human malignant melanoma  by Nishioka, Kenji
Volume 80. number 1 FEBS LETTERS August 1911 
CONVERSION OF PARTICULATE TYROSINASE TO SOLUBLE FORM AND TO 
DESIALYLATED TYROSINASE IN HUMAN MALIGNANT MELANOMA 
Kenji NISHIOKA 
Departments of Surgery/Surgical Research Laboratory and Biochemistry, The University of Texas System Cancer Center, 
M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77030, USA 
Received 9 May 1977 
Revised version received 14 June 1977 
1. Introduction 
Studies of mammalian tyrosinase (o&phenol: 02 
oxidoreductase, EC 1.10.3.1) a key enzyme in 
melanogenesis, have been conducted principally with 
soluble forms (T’ faster, T2 slower migrating tyrosin- 
ases by gel electrophoresis) obtained from mouse and 
hamster melanoma [l--S] and these T’ and T2 
tyrosinases are considered as isozymes [ 5,6] , However, 
mammalian melanocytes are known to contain active 
tyrosinase in both soluble and insoluble melanosome 
(melanin-producing organelle)bound (T3) forms [2,3] 
The majority of tyrosinase activity from mouse and 
human melanoma tissue is in particulate form [3,6,7] . 
Recently it has been shown by serological studies that 
human soluble tyrosinase is a glycoprotein [8]. This 
communication describes the partial purification of 
tyrosinase with concanavalin A (Con A) affinity 
chromatography and demonstrates the interconversion 
of the different enzymes forms (T' , T2, and T3). 
2. Materials and methods 
Human malignant melanoma tissue was obtained 
from metastatic deposits in the liver of a patient with 
disseminated melanoma and kept in a Revco at -75°C. 
It was thawed, minced, and homogenized by a 
Polytron (Brinkman Instruments) for a total period of 
1 min at 4°C in 10 volumes of medium A (50 mM 
sodium phosphate pH 7.0,0.25 M sucrose, 25 mM 
KCl, 4 mM MgC12 and 4 mM phenylmethylsulfonyl 
fluoride (Sigma)). This homogenate was centrifuged 
at 700 X g for 10 min. The supematant obtained was 
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further centrifuged at 100 000 X g for 1 h. This 
supernatant was used as soluble tyrosinase fraction. 
The pellet containing melanosomes was washed by 
suspending it in medium A and centrifuging twice to 
eliminate any contaminating soluble tyrosinase. It 
was then subjected to a tyrosinase solubilization step, 
in which melanosomes were suspended at 5 mg 
protein/ml in 0.05 M Tris/HCl pH 7.4 with 0.5% 
(w/v) sodium cholate by sonication. After stirring for 
30 min, this suspension was centrifuged at 100 000 X g 
for 1 h. The supernatant was then subjected to 
(NH4)2S04 fractionation after dialysis against 10 mM 
Tris/HCl (pH 7.4), containing 0.1% sodium cholate. 
No activity was detected in the pellet. The precipitate 
obtained from the 40 to 60% (NH4)2S04 saturation 
range was dissolved into 4 mM sodium phosphate 
(pH 7.0), with 0.1% (v/v) Triton X-100, and dialyzed 
against the same buffer for Con A-Sepharose (Pharma- 
cia) affinity chromatography. 
Tyrosinase activity was measured by oxidation of 
L-3,4-dihydroxyphenylalanine (DOPA) as described 
by Pomerantz and Li [9] , but carried out at 37°C 
utilizing a Gilford Stasar III equipped with a data lister. 
In this study, 1 unit of tyrosinase is defined as the 
amount that will catalyze the transformation of 
1 pmole of DOPA per min at 37°C. To confirm the 
identity of tyrosinase, each prepared tyrosinase 
fraction was also examined for tyrosine hydroxyla- 
tion activity [9] . Protein was measured by the method 
of Lowry et al. [IO]. When Triton X-100 was present, 
each tube was centrifuged at 1000 X g for 10 min 
before reading the absorbance as described by 
ChandraRajan and Klein [ 1 I] . 
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Utilizing Davis’ method [ 121 , polyacrylamide gel 
electrophoresis (7%) was carried out in Canalco system 
at 4°C with 3 mA per column (6.5 X 140 mm) using 
a standard Tris-glycine buffer system and 2.5% 
stacking gel. When the presence of Triton X-100 was 
required, 0.1% was included in all gels and tank 
buffers. For tyrosinase activity staining, the gel was 
rinsed with 0.2 M sodium phosphate buffer (pH 6.8), 
then incubated in 0.3% (w/v) DOPA solution in 0.1 M 
sodium phosphate buffer (pH 6.8), for 45 min at 
37°C. For preparation purposes, tyrosinase was 
extracted from gels containing 200 pg protein in the 
following manner: the gel, after electrophoresis, was 
kept in 0.2 M sodium phosphate buffer pH 6.8 for 
10 min. The reference gel was stained with DOPA. 
The portion corresponding to the DOPA positive area 
on the reference gel was cut off. The gel fragments 
were homogenized in 5 ml of 0.2 M sodium phosphate 
buffer (pH 6.8), and centrifuged at 3000 X g for 
10 min. The supernatant containing tyrosinase was 
concentrated by an Amicon standard UF cell using 
PM-10 membrane. Neuraminidase fVibriu cholerue) 
was obtained from Behring Diagnostics and the 











IO 20 30 40 50 
Fraction Number 
3. Results and discussion 
Soluble tyrosinase and sodium cholate-solubilized 
tyrosinase were partially purified by Con A-Sepharose 
column as shown in fig.1. The affinity chromatog- 
raphy for solubilized tyrosinase was carried out in 
the presence of 0.1% (v/v) Triton X-100 to avoid 
aggregation (fig.lb). Tyrosinase was never eluted 
with even the highest possible concentration of 
a-methyl-D-mannoside until the column temperature 
was raised. This suggests a high mannose content in 
this enzyme. 
To examine the possibility of proteolytic conver- 
sion of particulate tyrosinase to soluble form, solu- 
bilized tyrosinase was treated with trypsin and the 
result of this time-course-experiment is shown in 
fig.2. Upon trypsin digestion, the majority of solu- 
bilized tyrosinase was converted to a fast-migrating 
active tyrosinase in 6 h as shown by gel electropho- 
resis. The detergent-solubilized T3 tyrosinase seems 
to be an intact melanosomal tyrosinase giving a 
definite band in gel electrophoresis in the presence 
of Triton X-100. The stability of the trypsin-cleaved 
tyrosinase against further tryptic action appears to 









Fig.1. (a) Con A affinity column chromatographies ot soluble tyrosinase and (b) sodium cholate-solubtiized tyrosinase. Tyrosinase 
fractions were prepared as described in Materials and methods. Contaminating proteins were eluted by buffer I (4 mM potassium 
phosphate pH 7.0, 1 M KU), KC1 was then eliminated by buffer II (4 mM potassium phosphate pH 7.0) washing, and the flow 
was stopped. Column temperature was raised from 4°C to 28°C and tyrosinase was eluted by buffer III (4 mM potassium phos- 
phate (pH 7.0), 1 M cY-methyl-D-mannoside). Flow rate was 15 ml/h and 2 ml was collected in each fraction. Aliquots were taken 
for measurements of tyrosinase activity and protein concentration. Column sizes were 1.4 X 2 cm (a) and 1.2 X 7 cm (b). Proteins 
applied to each column were 1.6 mg (a) and 28.2 mg (b). Column b was run throughout with 0.1% (v/v) Triton X-100 in the 
solutions. 
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Fig.2 Time course of tryptic cleavage of solubilized tyrosinase 
examined by 7% polyacrylamide gel electrophoresis in the 
presence of 0.1% Triton X-100. Partially purified solubilized 
tyrosinase (E) was incubated with trypsin (T) at 37°C in 10 
mM Tris/HCl (pH 8.1), with 10 mM CaCl, for the period of 
hours as indicated in [ 1. The final composition of the 
reaction mixture was as follows: tyrosinase, 0.2 mg/ml; 
TPCK-trypsin, 0 or 0.2 (for up to 6 h incubation) or 0.4 mg/ 
ml (for a longer than 6 h incubation, trypsin was increased 
to 0.4 mg/ml after 9 h incubation). Two I.rg of tyrosinase 
sample was applied to each gel. After electrophoresis, gels 
were stained by DOPA as described in Materials and methods. 
Tyrosinase migrated from top (cathode) to bottom (anode). 
India ink indicates the position of the front marker dye, 
bromophenol blue (BPB). Note that tyrosinase incubated 
alone released no fast-migrating tyrosinase. 
site susceptible to proteolytic action. This tryptic 
conversion is also in agreement with the results 
obtained by Miyazaki and Seiji [ 141 and Quevedo 
et al. [ 151, in which mouse melanosomes were 
treated with trypsin, causing release of soluble tyro- 
sinase. This fast-migrating trypsincleaved tyrosinase 
was prepared utilizing the gel electrophoresis ystem 
as described in Methods, then treated with neuramini- 
dase, and the effect of neuraminidase treatment 
Fig.3. Polyacrylamide gel electrophoresis pattern of neur- 
aminidase-treated tyrosinase. Trypsin-cleaved tyrosinase was 
prepared as described in Materials and methods, and treated 
with neuraminidase at 37°C in 5 mM potassium phosphate 
(pH 7.0), 50 mM KC1 and 1 mM CaCl,. Final composition of 
the reaction mixture was as follows: tyrosinase, 0.5 mg/ml 
neuraminidase, 0 or 1 unit/ml. Ten pg equivalents of tyrosin- 
ase were applied to each gel. After electrophoresis, gels were 
stained by DOPA. (1) Trypsin-cleaved tyrosinase, (2) soluble 
tyrosinase containing T’ and T’ tyrosinases, (3) trypsin- 
cleaved tyrosinase treated with neuraminidase for 15 min, 
(4) trypsin-cleaved tyrosinase treated with neuraminidase 
for 30 min. 
examined by gel electrophoresis, as shown in tig.3. 
The result indicated that trypsin-cleaved tyrosinase 
(RF: 0.51) corresponded to T’ (RF: 0.51) and upon 
neuraminidase treatment shifted to RF 0.37 which 
corresponds to the T* tyrosinase position (RF : 0.36) 
indicating overall conversion of T3 + T’ + T2. To 
further confirm this T’ -+ T2 conversion, T’ and T2 
tyrosinases were prepared by gel electrophoresis, and 
treated with neuraminidase. As shown in fig.4, while 
T’ tyrosinase shifted to T2 position upon neuramini- 
dase treatment, T2 retained its position. 
These data strongly support the dynamic conversion 
pathway of T3 + T’ + T2 rather than their existence 
as separate enzymes. The presence of carbohydrate 
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of human melanoma tissue culture lines, although 
inclusion of phenylmethylsulfonyl fluoride during 
the homogenization step tends to lessen the ratio of 
soluble tyrosinase relative to particulate form. This 
aspect requires further studies. 
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Fig.4. Effect of neuraminidase treatments of T’ and T2 
tyrosinases examined by 7% polyacrylamide gel electropho- 
resis. T’ and T’ tyrosinases were prepared from partially 
purified soluble tyrosinase (fig.la) as described in Materials 
and methods and were treated with neuraminidase for 16 h 
otherwise as described in fig.3 legend. Fifty-nine c(g equi- 
valent tyrosinase were applied to each gel. Gels were stained 
by DOPA. T, : T’ tyrosinase, T, : T* tyrosinase, N: 
neuraminidase. 
moiety in soluble tyrosinase itself also suggests that 
soluble tyrosinase might stem from melanosome- 
bound tyrosinase. 
It has been reported that melanoma-bearing mice 
possess circulating serum tyrosinase which stems from 
the melanoma tissue and a similar report has appeared 
in conjunction with human melanoma patients [ 16 ] . 
On the basis of the above conversion scheme, circulat- 
ing tyrosinase should be T’ , since desialylated tyro- 
sinase containing a galactose end-group should be 
trapped by the liver, as shown by Ashwell and Morel1 
[ 171. Whether this conversion is a physiological 
process is not yet clear. Since there is much necrotic 
tissue inside the tumor mass, the release of lysosomal 
enzyme might play a role in this conversion. Yet, T’ 
and T2 tyrosinases can be observed in cytosol fractions 
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